Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2013

View Archived Issues

Ascorbix presents novel agents for cancer

Italian researchers patent new photosensitizing agents

Suzhou NeuPharma discloses novel arctigenin derivatives for cancer

HSCI obtains approval in Ukraine for Neovasculgen

Biosantech initiates phase I/II trial of synthetic AIDS vaccine Tat Oyi

Activin betaC expression plays a role in the progression of prostate disease

HAT-01: a novel herbal preparation for the treatment of atopic dermatitis

Katanin enzyme complexes necessary for male fertility

UCB reflects on achievements of 2012

Researchers at Ascendis Pharma synthesize novel prodrugs of paliperidone

Promethera Biosciences opens French site in phase I/II HepaStem trial

BioLineRx's candidate for severe and persistent asthma to enter main pipeline

Novan Therapeutics reports preclinical data for topical sebum inhibitor

Trophos confirms positive interim review for pivotal olesoxime trial

Life Technologies signs stem cell research agreement

NIBP expression shows partial correlation with breast tumor staging

FDA accepts filing of BLA for recombinant factor IX Fc fusion protein

FDA agrees with La Jolla Pharmaceutical's proposed IND for LJPC-501

Immuron reports preclinical data for IMM-529

Sarepta Therapeutics reports data from non-human primate study of AVI-7288

VX-787 shows antiviral activity in phase II influenza challenge study

EMA grants orphan drug status to Prothena's candidate for amyloid light-chain amyloidosis

Researchers at Merck KGaA design new RON inhibitors

HH1.5 shows potential as a novel biomarker in prostate cancer

Verona's RPL-554 demonstrates anti-inflammatory activity in exploratory trial

Health Canada declines to approve Theratechnologies' NDS for Egrifta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...